Cell Signaling Technology, Inc. (CST) is a privately held firm that develops and manufactures antibodies, ELISA kits, ChIP kits, proteomic kits, and other reagents used to investigate the cell signalling pathways that influence human health.

CST maintains an in-house research programme, particularly in the field of cancer research, and has published numerous scientific articles in scholarly journals.

Cell Signaling Technology was founded in 1999 by experts from New England Biolabs’ Cell Signaling department (NEB).

In late 2005, CST relocated its United States headquarters from the Cummings Center in Beverly, Massachusetts, to the historic King’s Grant Inn in Danvers, Massachusetts.

In 2007, the U.S. Green Building Council certified the present headquarters as LEED (Leadership in Energy and Environmental Design) compliant following major renovations.

CST increased its international activities in 2008 and 2009 by opening subsidiary offices in the People’s Republic of China, Japan, and the Netherlands.

In 2013, CST’s production division relocated to an ISO9001-accredited facility in Beverly, Massachusetts.

– Cell Signaling Technology was designated one of the “Top 100 Places to Work” by the Boston Globe in a 2009-2013 poll.

CST is also active in the creation of novel tools for signalling analysis and mechanistic cell biology research, especially in the field of cancer research.

PhosphoSitePlus is a web-based bioinformatics resource that provides information about post-translational modifications (PTMs) in human, mouse, and rat proteins.

Phosphorylation, acetylation, methylation, ubiquitylation, and glycosylation are among the PTMs that are curated.

This publicly available online resource is partially supported by a grant from the NIH, most recently under the BD2K initiative.